Pharmaceutical Technology
FEBRUARY 13, 2023
While several therapeutics are available for treating symptoms associated with epilepsy, researchers and patients have strongly called out the need for more holistic treatments that would address the condition as a whole.
Bio Pharma Dive
FEBRUARY 14, 2023
Through social media, virtual meetings and mentorship programs, a growing group of entrepreneurs is looking for new ways to build drug companies
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 14, 2023
Pfizer CEO's texts with European Commission chief trigger new NYT lawsuit kdunleavy Tue, 02/14/2023 - 10:29
Pharma Times
FEBRUARY 17, 2023
Research concerning candidate VLA15 has been discontinued across certain trial sites
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
This webinar will go over the FDA's guidance on pharmacological and toxicological considerations for optimizing doses for prescription drugs.
Pharmaceutical Technology
FEBRUARY 17, 2023
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage.
Bio Pharma Dive
FEBRUARY 17, 2023
Apellis’ Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 15, 2023
Neoantigen vaccine candidate, SLATE-KRAS has demonstrated early evidence of efficacy
Pharmaceutical Technology
FEBRUARY 14, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 14, 2023
Syena will develop TCR-based natural killer cell therapies, building on research done by MD Anderson’s Katy Revzani and using technology from Replay
Fierce Pharma
FEBRUARY 17, 2023
Apellis wins FDA approval for first geographic atrophy drug fkansteiner Fri, 02/17/2023 - 18:06
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Pharma Times
FEBRUARY 16, 2023
First subject dosed with company’s SPL028 – a proprietary deuterated DMT candidate
Pharmaceutical Technology
FEBRUARY 15, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 13, 2023
The company said its modified contract with the federal government, which comes ahead of a planned transition to private market sales, will help it develop an updated version of its vaccine
Outsourcing Pharma
FEBRUARY 16, 2023
Scientists can now dramatically reduce trial-and-error experimentation and uncover risks early thanks to an artificial intelligence solutions company. Clinical Development
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Pharma Times
FEBRUARY 14, 2023
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
Pharmaceutical Technology
FEBRUARY 15, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 16, 2023
The company’s platform technology is built on research from Zhang’s lab at the Broad Institute, which focuses on a proteins that could be used to package and deliver nucleic acids
BioSpace
FEBRUARY 15, 2023
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff 2/16/2023
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Pharma Times
FEBRUARY 17, 2023
Company has reported strong momentum among the early-stage businesses it invested in last year
Pharmaceutical Technology
FEBRUARY 14, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 17, 2023
Shaw, who joined Gilead in 2019 from Eli Lilly, helped build Kite into a leading producer of cell therapies, convincing Wall Street skeptics in the process
BioSpace
FEBRUARY 16, 2023
Pfizer/Valneva Trial at Risk After Possible GCP Violations 2/17/2023
Pharma Times
FEBRUARY 13, 2023
Partnership will focus on essential new therapies across neurodegenerative diseases
Pharmaceutical Technology
FEBRUARY 16, 2023
The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development.
Bio Pharma Dive
FEBRUARY 17, 2023
Violations of study standards by a “third-party clinical trial site operator” prompted the partners to stop evaluating a large portion of the volunteers in their trial, the largest test of a Lyme disease vaccine in decades
Fierce Pharma
FEBRUARY 16, 2023
Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod fkansteiner Thu, 02/16/2023 - 14:12
Pharma Times
FEBRUARY 13, 2023
Collaboration continues to be focused on reaching locations where temporary clinics cannot be easily set up
Pharmaceutical Technology
FEBRUARY 14, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 16, 2023
Following a patient death and difficulty enrolling study participants, the company is laying off a third of its staff and ending a pair of studies for a two-decade-old program once owned by Novartis
Fierce Pharma
FEBRUARY 15, 2023
After J&J's Texas two-step stumble, another talc plaintiff heads to trial: report fkansteiner Wed, 02/15/2023 - 11:10
XTalks
FEBRUARY 16, 2023
It’s been a year since Indorsia Pharmaceuticals’ “Seize the Night and Day” insomnia awareness ad campaign featuring Jennifer Aniston first aired on TV, and the numbers are in. In 2022, Indorsia’s insomnia drug Quviviq (daridorexant) brought in a total of ₣6.5 million CHF (about $7 million USD).
Pharmaceutical Technology
FEBRUARY 15, 2023
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence.
Bio Pharma Dive
FEBRUARY 13, 2023
Reed, who is leaving for a “new opportunity outside Sanofi,” oversaw the recent transformation of the French company’s pipeline of drug programs
Expert insights. Personalized for you.
264 
Let's personalize your content